Selectivity at ligand targets
Key to terms and symbols		Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference BMP-6 Hs Fusion protein Binding - - - 3 ⤷ [3] myostatin Hs Fusion protein Binding - - - 3 ⤷ [3]

Targets where the ligand is described in the comment field
Target	Comment
activin A receptor type 2B	Ligand traps (decoys) based on the ectodomain structure of activin A receptor type 2B (ActRIIB) are proposed for therapeutic benefit in diseases/conditions that are associated with pathway activation by TGFβ superfamily ligands such as the TGFβs, bone morphogenic proteins (BMPs), activins, and Nodal. Two approved drugs, sotatercept and luspatercept, are ActRIIA/IIB and ActRIIB traps that are used to treat pulmonary arterial hypertension (PAH) and anemias, respectively. Since these original approvals, GSK/35Pharma have developed ActRIIB-based ligand trap HS235, which is proposed to selectively bind pathological activins and GDFs whilst sparing BMP-9 and BMP-10 which are essential for maintaining blood vessel and lymphatic system integrity. HS235 is intended to treat PAH, heart failure and obesity [10]. Keros Therapeutics have developed RKER-012 which also intended for PAH, via neutralisation of ligands including activins A and B, GDFs 8 (myostatin) and 11 [4].